These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20101016)

  • 41. [Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].
    Mühlbauer B; Timm J
    Med Klin (Munich); 2006 Aug; 101(8):673-5; author reply 678-9. PubMed ID: 17051669
    [No Abstract]   [Full Text] [Related]  

  • 42. How to avoid future Vioxx-type scandals.
    Prescrire Int; 2005 Jun; 14(77):115-7. PubMed ID: 15984108
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quebec allows Vioxx class-action suit.
    Sibbald B
    CMAJ; 2007 Jan; 176(1):20. PubMed ID: 17200378
    [No Abstract]   [Full Text] [Related]  

  • 44. Institutional review boards must conduct safety review.
    Maloney DM
    Hum Res Rep; 2005 Feb; 20(2):3. PubMed ID: 15839005
    [No Abstract]   [Full Text] [Related]  

  • 45. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making.
    Etminan M; Gill S; Fitzgerald M; Samii A
    J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Scientific publishing. Echoing other cases, NEJM says Vioxx Safety data withheld.
    Couzin J
    Science; 2005 Dec; 310(5755):1755. PubMed ID: 16357236
    [No Abstract]   [Full Text] [Related]  

  • 47. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
    Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
    Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Cyclooxygenase inhibitors: a never ending story?].
    Macrì R; Manfredi C
    G Ital Cardiol (Rome); 2006 Jul; 7(7):505-7. PubMed ID: 16977790
    [No Abstract]   [Full Text] [Related]  

  • 49. Under surveillance.
    Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
    [No Abstract]   [Full Text] [Related]  

  • 50. Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.
    Roth-Cline MD
    Circulation; 2006 May; 113(18):2253-9. PubMed ID: 16684875
    [No Abstract]   [Full Text] [Related]  

  • 51. NEJM "failed its readers" by delay in publishing its concerns about VIGOR trial.
    Dobson R
    BMJ; 2006 Jul; 333(7559):116. PubMed ID: 16840463
    [No Abstract]   [Full Text] [Related]  

  • 52. The Vioxx® legacy: Enduring lessons from the not so distant past.
    McIntyre WF; Evans G
    Cardiol J; 2014; 21(2):203-5. PubMed ID: 24752949
    [No Abstract]   [Full Text] [Related]  

  • 53. [Funtional phase IV?].
    Heinzl S
    Med Monatsschr Pharm; 2005 Jan; 28(1):1. PubMed ID: 15693597
    [No Abstract]   [Full Text] [Related]  

  • 54. Does perioperative administration of rofecoxib improve analgesia after spine, breast and orthopaedic surgery?
    Riest G; Peters J; Weiss M; Pospiech J; Hoffmann O; Neuhäuser M; Beiderlinden M; Eikermann M
    Eur J Anaesthesiol; 2006 Mar; 23(3):219-26. PubMed ID: 16430794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FDA warns Merck over its promotion of rofecoxib.
    Josefson D
    BMJ; 2001 Oct; 323(7316):767. PubMed ID: 11588068
    [No Abstract]   [Full Text] [Related]  

  • 56. [The withdrawal of Vioxx: how did the patients react?].
    Rognstad S; Straand J
    Tidsskr Nor Laegeforen; 2006 May; 126(10):1326-7. PubMed ID: 16691268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implications of the rofecoxib trials.
    Kozma CM
    Manag Care Interface; 2005 Oct; 18(10):61-2. PubMed ID: 16265937
    [No Abstract]   [Full Text] [Related]  

  • 58. Time-to-event analyses for long-term treatments--the APPROVe trial.
    Lagakos SW
    N Engl J Med; 2006 Jul; 355(2):113-7. PubMed ID: 16801354
    [No Abstract]   [Full Text] [Related]  

  • 59. Rosiglitazone: what went wrong?
    Cohen D
    BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
    [No Abstract]   [Full Text] [Related]  

  • 60. Medical journal criticizes Merck over Vioxx data.
    Berenson A
    N Y Times Web; 2005 Dec; ():A1, C13. PubMed ID: 16456990
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.